id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-259957-temt8b6f	Brown, Ronald	Hydroxychloroquine and “off-label” utilization in the treatment of oral conditions	2020-04-11		.txt	text/plain	861	55	44	Both drugs are approved to treat malaria, lupus, and rheumatoid arthritis but must still be assessed in clinical trials before being declared a safe and effective COVID-19 treatment. However, it is utilized extensively by both physicians and dentists (oral medicine clinicians) in the treatment of rheumatologic conditions, such as systemic lupus erythematosus, Sjogren syndrome, rheumatoid arthritis, chronic ulcerative stomatitis, immune thrombocytopenia purpura, lichen planopilaris, and oral lichen planus. Therefore, there appears to be the possibility of additive drug interactions when prescribing HCQ to patients already taking citalopram and other drugs that significantly prolong the QT duration and increase the risk of a torsade de pointes arrhythmia. However, oral medicine clinicians and other health care providers should be advised of the potential issues with the use of HCQ, such as drugÀdrug interactions, the additive toxicity of QT duration prolongation, and the association with sudden death, in the treatment of older patients.	./cache/cord-259957-temt8b6f.txt	./txt/cord-259957-temt8b6f.txt